DALLAS, May 27, 2026
Nanoscope Therapeutics Inc., a biotechnology company developing disease-agnostic therapies for retinal degeneration and vision impairment, has announced a strategic collaboration with InspiroGene by McKesson to support U.S. commercialization and distribution services for its lead retinal therapy candidate, MOGENRY™, pending regulatory approval. The partnership marks a major milestone in Nanoscope’s commercialization readiness strategy as the company advances what could become the first optogenetic gene therapy launched in the U.S. retinal disease market. The collaboration will focus on specialty pharmacy support, specialty distribution, patient hub services, and supply chain management to support future commercial operations across the United States.
Nanoscope stated that InspiroGene by McKesson will help establish a streamlined commercialization infrastructure capable of supporting healthcare providers, specialty clinics, and patients receiving MOGENRY therapy following potential regulatory approvals. Company executives emphasized that the agreement is intended to strengthen inventory management, patient access, order fulfillment, and regulatory compliance systems as commercialization preparations accelerate. The announcement highlights growing momentum in the advanced retinal therapy market, where gene therapies and optogenetic technologies are increasingly being explored to address severe vision loss caused by retinal degenerative diseases.
MOGENRY Advances Optogenetic Vision Restoration
MOGENRY is based on Nanoscope’s proprietary MCO optogenetic platform, an investigational disease-agnostic retinal therapy designed to restore vision in patients suffering from photoreceptor degeneration. Unlike traditional gene therapies that often target single-gene mutations, the MCO platform is designed to function across multiple retinal degenerative diseases without requiring genetic testing, invasive surgical implants, or external light-intensifying devices.
The therapy works by activating highly dense bipolar retinal cells and converting them into light-sensitive cells capable of utilizing existing visual circuitry after photoreceptor loss occurs. According to Nanoscope, the treatment is delivered through a one-time, in-office intravitreal injection, potentially simplifying treatment logistics and expanding accessibility within existing retinal care settings.
Advertisement
The company’s lead clinical programs currently target patients with Retinitis Pigmentosa (RP), Stargardt disease (SD), and Geographic Atrophy (GA), all conditions associated with significant unmet medical needs and progressive vision loss. Nanoscope reported that its technology is specifically designed to reduce patient treatment burden while supporting broader clinical applicability for patients suffering from retinal degeneration.
Positive Clinical Progress Supports Commercialization Plans
Nanoscope’s commercialization preparations follow encouraging clinical progress across multiple ophthalmology programs. The company previously announced positive findings from the RESTORE Phase 2b/3 multicenter clinical trial evaluating MCO-010 in patients with Retinitis Pigmentosa. Following those results, Nanoscope initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). If approved, MCO-010 could potentially become a first-in-class optogenetic therapy and establish a new treatment paradigm for inherited retinal diseases.
The company also reported promising data from the STARLIGHT Phase 2 clinical trial evaluating MCO-010 in Stargardt disease patients. Based on those findings, Nanoscope plans to initiate a Phase 3 registrational study during 2026. Additional pipeline expansion activities are also underway, including planned Phase 2 development in Geographic Atrophy and investigational programs targeting Leber Congenital Amaurosis (LCA).
MCO-010 has already received multiple important regulatory designations from the FDA, including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) status for retinal disease indications. The therapy has also obtained orphan and expedited pathway recognitions from regulators in Japan and Europe, reflecting increasing global interest in next-generation retinal gene therapies.
Advanced Retinal Therapies Continue Expanding
The agreement between Nanoscope Therapeutics and InspiroGene by McKesson reflects broader pharmaceutical and biotechnology industry investment in advanced therapies for ophthalmic diseases. Retinal degeneration disorders affect millions of patients globally, while currently available treatment options remain limited for many inherited and degenerative vision disorders.
Industry analysts believe optogenetic therapies may represent one of the most transformative emerging areas in ophthalmology because they aim to restore functional vision independent of specific genetic mutations. The addition of specialty commercialization partners such as InspiroGene is increasingly viewed as critical for ensuring efficient patient access, regulatory compliance, specialty distribution, and long-term support infrastructure for complex gene therapy products entering the market.
The latest collaboration further positions Nanoscope Therapeutics among the leading biotechnology companies advancing innovative retinal therapies designed to address major unmet medical needs in ophthalmology and vision restoration.
Source: Nanoscope Therapeutics press release
